Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in Uganda

被引:29
作者
Fillekes, Quirine [1 ]
Natukunda, Eva [2 ]
Balungi, Jackie [3 ]
Kendall, Lindsay [6 ]
Bwakura-Dangarembizi, Mutsa [4 ]
Keishanyu, Rosette [2 ]
Ferrier, Alex [6 ]
Lutakome, Joseph [5 ]
Gibb, Diana M. [6 ]
Burger, David M. [1 ]
Walker, A. Sarah [6 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, NL-6525 GA Nijmegen, Netherlands
[2] Joint Clin Res Ctr, Kampala, Uganda
[3] Pediat Infect Dis Ctr, Mulago, Uganda
[4] Univ Zimbabwe, Sch Med, Dept Paediat & Child Hlth, Harare, Zimbabwe
[5] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda
[6] MRC Clin Trials Unit, London, England
基金
英国医学研究理事会;
关键词
children; efavirenz; HIV-1; pharmacokinetics; Uganda; HIV-1-INFECTED CHILDREN; ANTIRETROVIRAL THERAPY; HIGH PREVALENCE; CYP2B6; POLYMORPHISM; LAMIVUDINE; TRIAL; INDINAVIR; VARIANTS; WEIGHT;
D O I
10.1097/QAI.0b013e318235e560
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate international pediatric efavirenz dosing recommendations using full pharmacokinetic (PK) information. Design: Open-label, multicenter, PK study. Methods: Forty-one HIV-infected Ugandan children (3-12 years) on efavirenz + lamivudine + abacavir were enrolled in a study of twice-daily to once-daily lamivudine + abacavir 36 weeks after antiretroviral therapy initiation in the ARROW trial. Once-daily efavirenz doses were 200, 250, 300, 350 mg for children weighing 10 to <15, 15 to <20, 20 to <25, 25 to <30 kg, respectively, using 200/50 mg capsules or halved 600 mg tablets in case of 300 and 350 mg doses. Intensive plasma PK sampling (t = 0, 1, 2, 4, 6, 8, 12 hours postobserved ingestion) was performed at steady state (PK1) and repeated 4 weeks later (PK2, including a further 24-hour sample). Results: Forty-one and 39 children had evaluable efavirenz profiles at PK1 and PK2, respectively. Seventeen (41%) were boys. Five, 16, 17, 3 were in the 10 to <15, 15 to <20, 20 to <25, 25 to <30 kg weight bands. The geometric mean (%CV) the area under the concentration-time curve 0-24 hours postdose was 50.8 (90.8%) and 55.5 (82.7%) h.mg.L-1 at PK1 and PK2, respectively. Six children at PK1 and 7 at PK2 had subtherapeutic C-8h and/or C-12h (<1.0 mg/L), 7 of 41 (17%) at either visit. At PK2, 15 of 39 (38%) children had C-24h <1.0 mg/L (median (interquartile range) [range] 1.1 (0.7-2.9) [0.3-18.4]). Ten children at PK1 and 11 at PK2 had C-8h and/or C-12h >4.0 mg/L; 12 of 41 (29%) at either visit. Conclusions: African children aged 3-12 years, on efavirenz dosed according to 2006 WHO/manufacturer's recommendations, had lower and highly variable efavirenz PK parameters compared with adult data from manufacturer's leaflet. There were no differences across weight bands, suggesting no major effect of using half tablets. Higher pediatric efavirenz doses, as per WHO 2010 recommendations, should be used and investigated further but may risk increasing the proportion of children with potentially toxic levels.
引用
收藏
页码:392 / 398
页数:7
相关论文
共 24 条
[11]   Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].
Marzolini, C ;
Telenti, A ;
Decosterd, LA ;
Greub, G ;
Biollaz, J ;
Buclin, T .
AIDS, 2001, 15 (01) :71-75
[12]   Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial [J].
Musiime, Victor ;
Kendall, Lindsay ;
Bakeera-Kitaka, Sabrina ;
Snowden, Wendy B. ;
Odongo, Florence ;
Thomason, Margaret ;
Musoke, Philippa ;
Adkison, Kimberly ;
Burger, David ;
Mugyenyi, Peter ;
Kekitiinwa, Adeodata ;
Gibb, Diana M. ;
Walker, A. Sarah .
ANTIVIRAL THERAPY, 2010, 15 (08) :1115-1124
[13]   High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe [J].
Nyakutira, Christopher ;
Roshammar, Daniel ;
Chigutsa, Emmanuel ;
Chonzi, Prosper ;
Ashton, Michael ;
Nhachi, Charles ;
Masimirembwa, Collen .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) :357-365
[14]  
Puthanakit T, 2009, ANTIVIR THER, V14, P315
[15]   High prevalence of subtherapeutic plasma concentrations of efavirenz in children [J].
Ren, Yuan ;
Nuttall, James J. C. ;
Egbers, Claire ;
Eley, Brian S. ;
Meyers, Tammy M. ;
Smith, Peter J. ;
Maartens, Gary ;
McIlleron, Helen M. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (02) :133-136
[16]  
Saitoh A, 2007, JAIDS-J ACQ IMM DEF, V45, P280
[17]   Body surface area estimation in children using weight alone: application in paediatric oncology [J].
Sharkey, I ;
Boddy, AV ;
Wallace, H ;
Mycroft, J ;
Hollis, R ;
Picton, S .
BRITISH JOURNAL OF CANCER, 2001, 85 (01) :23-28
[18]   Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults [J].
Staszewski, S ;
Morales-Ramirez, J ;
Tashima, KT ;
Rachlis, A ;
Skiest, D ;
Stanford, J ;
Stryker, R ;
Johnson, P ;
Labriola, DF ;
Farina, D ;
Manion, DJ ;
Ruiz, NM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) :1865-1873
[19]  
Heine R, 2008, ANTIVIR THER, V13, P779
[20]   Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study [J].
van Leth, F ;
Phanuphak, P ;
Ruxrungtham, K ;
Baraldi, E ;
Miller, S ;
Gazzard, B ;
Cahn, P ;
Lalloo, UG ;
van der Westhuizen, IP ;
Malan, DR ;
Johnson, MA ;
Santos, BR ;
Mulcahy, F ;
Wood, R ;
Levi, GC ;
Reboredo, G ;
Squires, K ;
Cassetti, I ;
Petit, D ;
Raffi, F ;
Katlama, C ;
Murphy, RL ;
Horban, A ;
Dam, JP ;
Hassink, E ;
van Leeuwen, R ;
Robinson, P ;
Wit, FW ;
Lange, JMA .
LANCET, 2004, 363 (9417) :1253-1263